

# The science of contrast media



## **VISIPAQUE™** (IODIXANOL) INJECTION

### IMPORTANT SAFETY INFORMATION ABOUT VISIPAQUE

#### WARNING: NOT FOR INTRATHECAL USE

Inadvertent intrathecal administration may cause death, convulsions/seizures, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, rhabdomyolysis, hyperthermia, and brain edema.

Please see additional Important Safety Information, including Boxed Warning, [here](#), and full Prescribing Information, [here](#).

## PRODUCT INDICATIONS AND USE — VISIPAQUE (IODIXANOL)

### Intra-Arterial Procedures

**Adult and pediatric patients 12 years of age and older:** Intra-arterial digital subtraction angiography (270 and 320 mg iodine/mL); angiocardigraphy (left ventriculography and selective coronary arteriography), peripheral arteriography, visceral arteriography, and cerebral arteriography (320 mg iodine/mL). **Pediatric patients less than 12 years of age:** Angiocardigraphy, cerebral arteriography, and visceral arteriography (320 mg iodine/mL)

### Intravenous Procedures

**Adult and pediatric patients 12 years of age and older:** Computed tomography (CT) imaging of the head and body (270 and 320 mg iodine/mL); excretory urography (270 and 320 mg iodine/mL); peripheral venography (270 mg iodine/mL); coronary computed tomography angiography (CCTA) to assist in the diagnostic evaluation of patients with suspected coronary artery disease (320 mg iodine/mL). **Pediatric patients less than 12 years of age:** CT imaging of the head and body (270 mg iodine/mL); excretory urography (270 mg iodine/mL)

## IMPORTANT SAFETY INFORMATION ABOUT VISIPAQUE

### WARNING: NOT FOR INTRATHECAL USE

Inadvertent intrathecal administration may cause death, convulsions/seizures, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, rhabdomyolysis, hyperthermia, and brain edema.

### CONTRAINDICATION:

Visipaque injection is contraindicated for intrathecal use.

### WARNINGS AND PRECAUTIONS:

- **Hypersensitivity Reactions:** Life-threatening or fatal reactions can occur. Most severe reactions develop shortly after the start of the injection, but reactions can occur up to hours later. Always have emergency equipment and trained personnel available.
- **Contrast Induced Acute Kidney Injury:** Acute injury including renal failure can occur. Minimize dose and maintain adequate hydration to minimize risk.
- **Cardiovascular Reactions:** Life-threatening or fatal cardiovascular reactions, including hypotension, shock, and cardiac arrest have occurred with the use of Visipaque. Most deaths occur during injection or five to ten minutes later, with cardiovascular disease as the main aggravating factor. Use the lowest necessary dose of Visipaque in patients with congestive heart failure.
- **Thromboembolic Events:** Serious, rarely fatal, thromboembolic events causing myocardial infarction and stroke can occur during angiocardigraphy procedures with both ionic and nonionic contrast agents.
- **Extravasation and Injection Site Reactions:** Extravasation of Visipaque injection may cause tissue necrosis and/or compartment syndrome, particularly in patients with severe arterial or venous disease. Ensure intravascular placement of catheters prior to injection.
- **Thyroid Storm in Patients With Hyperthyroidism:** Thyroid storm has occurred after the intravascular use of iodinated contrast agents in patients with hyperthyroidism, or with an autonomously functioning thyroid nodule.

- **Thyroid Dysfunction in Pediatric Patients 0 to 3 Years of Age:** Thyroid dysfunction characterized by hypothyroidism or transient thyroid suppression has been reported after both single exposure and multiple exposures to iodinated contrast media. Among patients 0 to 3 years of age exposed to iodinated contrast media, thyroid dysfunction has been reported in 1% to 15% depending on the age of the patient and the dose of the iodinated contrast agent. Monitor these patients for thyroid function abnormalities and treat as clinically needed.
- **Hypertensive Crisis in Patients With Pheochromocytoma:** Hypertensive crisis has occurred after the use of iodinated contrast agents in patients with pheochromocytoma. Inject the minimum amount of contrast necessary, assess the blood pressure throughout the procedure, and have measures for treatment of a hypertensive crisis readily available.
- **Sickle Cell Crisis in Patients With Sickle Cell Disease:** Iodinated contrast agents when administered intravascularly may promote sickling in individuals who are homozygous for sickle cell disease.
- **Severe Cutaneous Adverse Reactions:** Severe cutaneous adverse reactions (SCARs) may develop from one hour to several weeks after intravascular contrast agent administration. These reactions include Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN), acute generalized exanthematous pustulosis (AGEP), and drug reaction with eosinophilia and systemic symptoms (DRESS). Avoid administering Visipaque to patients with a history of a SCAR to Visipaque.
- **Pediatric Use:** Pediatric patients at high risk of adverse reactions during and after administration of contrast agents include those with asthma, hypersensitivity to other medication and/or allergens, cyanotic and acyanotic heart disease, chronic heart failure, or a serum creatinine >1.5 mg/dL. Patients with immature renal function or dehydration may be at increased risk due to prolonged elimination of iodinated contrast agents.
- **Geriatric Use:** While no overall differences in safety or effectiveness were observed in patients >65 years, greater sensitivity regarding some older individuals cannot be ruled out.

### ADVERSE REACTIONS:

- Serious, life-threatening, and fatal reactions, mostly of cardiovascular origin, have been associated with the administration of iodine-containing contrast agents, including Visipaque Injection.
- Most common adverse reactions (incidence greater than 0.5%) in adult patients after Visipaque injection: Discomfort, warmth, pain; Cardiovascular: angina. Gastrointestinal: diarrhea, nausea, vomiting. Nervous System: agitation, anxiety, insomnia, nervousness, dizziness, headache, migraine, unusual skin sensations, sensory disturbance, fainting, sensation of spinning. Skin: itchy rash, severe itching, hives. Special Senses: Smell, taste, and vision alteration. Pediatric patients experienced similar adverse reactions.

Please see the full Prescribing Information, including Boxed Warning, [here](#), for additional important safety information.

To report SUSPECTED ADVERSE REACTIONS, contact GE HealthCare at 800 654 0118 (option 2, then option 1), or the FDA at 800 FDA 1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).





# The science of contrast media

Evolution  
of contrast  
media

Impact of  
osmolality

Utility of  
Visipaque



# Evolution of contrast media





Trends in tolerability

Changes in osmolality

Electrolyte enrichment

# The driving force of CM evolution has been tolerability<sup>1,2</sup>

While the basic form of x-ray CM is an iodinated benzene ring, agents differ in the structure of their side chains<sup>3,4</sup>

|           |               |   | Molecule   | Osmolality<br>(mOsm/kg H <sub>2</sub> O) | Iodine<br>atoms/<br>particle in<br>solution |
|-----------|---------------|---|--|--|---|
| Ionic     | 1950s<br>HOCM | Monomer<br>diatrizoate<br>iothalamate<br>metrizoate |    | 1270-2300                                | 3/2   |
|           | 1980s<br>LOCM | Dimer<br>ioxaglate                                  |    | 600                                      | 6/2   |
| Non-ionic | 1980s<br>LOCM | Monomer<br>iohexol<br>iopamidol<br>ioversol         |   | 521-915                                  | 3/1   |
|           | 1990s<br>IOCM | Dimer<br>iodixanol                                  |  | 290                                      | 6/1   |

R (from "radical") represent different side chains      Adapted from Aspelin P et al. 2006 + Jakobsen JA 2007.

## Developments include:<sup>2</sup>

- removing the ionic carboxyl group and its counter ion
- masking the hydrophobic core by long hydrophilic side chains
- linking two masked benzene rings together




CM, contrast medium/media  
HOCM, high osmolar CM  
IOCM, isosmolar CM  
LOCM, low-osmolar CM

1. Almén T. *Acta Radiol.* 1995; 36(Suppl.399):2-18.
2. Christiansen C. *Toxicology.* 2005;209(2):185-187.
3. Jakobsen JA. *Eur J Radiol.* 2007;62(Suppl.):s14-25.
4. Aspelin P. *Eur Radiol Suppl.* 2006;16(Suppl.4):D22-27.

Please see Important Safety Information about Visipaque, including Boxed Warning, on page 2 and Full Prescribing Information given to you before this meeting.

# Visipaque is the only CM for intravascular use that is isosmolar to blood at all concentrations

Because much of their toxicity is related to osmolality, a major focus in the evolution of CM has been the reduction of osmolality<sup>1,2</sup>



CM, contrast medium/media

1. Jakobsen JA. *Eur J Radiol.* 2007;62(Suppl.):s14-25.
2. Pedersen HK. *Acta Radiol. Suppl.* 1996;37(Suppl.405):1-31.
3. Davidson C et al. *Am J Cardiol.* 2006;98(Suppl.):42-58k.
4. Moritz ML. *Ped Nephrol* 2019;34(7):1299-1300.

## IMPORTANT SAFETY INFORMATION ABOUT VISIPAQUE

### WARNINGS AND PRECAUTIONS:

- **Extravasation and Injection Site Reactions:** Extravasation of Visipaque injection may cause tissue necrosis and/or compartment syndrome, particularly in patients with severe arterial or venous disease. Ensure intravascular placement of catheters prior to injection.
- **Thyroid Storm in Patients With Hyperthyroidism:** Thyroid storm has occurred after the intravascular use of iodinated contrast agents in patients with hyperthyroidism, or with an autonomously functioning thyroid nodule.

Please see additional Important Safety Information about Visipaque, including Boxed Warning, on page 2 and Full Prescribing Information given to you before this meeting.

# Iodixanol is made isosmolar and isotonic with the enrichment of key electrolytes

Aqueous solutions of iodixanol actually have a lower osmolality than blood<sup>1</sup>

The osmolality gap is filled by the addition of sodium and calcium<sup>2</sup>

NaCl

CaCl<sup>2</sup>

The ratio between sodium and calcium in Visipaque is the same as the physiological ratio in blood

| Concentration<br>(mg l/mL) | Osmolality<br>(mOsmol/kg water) | Viscosity<br>(cP) |      |
|----------------------------|---------------------------------|-------------------|------|
|                            |                                 | 20°C              | 37°C |
| 320                        | 290                             | 26.6              | 11.8 |
| 270                        | 290                             | 12.7              | 6.3  |

20 °C: Room temperature  
37 °C: Warmed to body temperature

Adapted from Visipaque [prescribing information] 2020<sup>3</sup>



1. Eivindvik K, Sjogren CE. *Acta Radiol.* 1995; 36(Suppl.399):32-38.  
2. Almén T. *Acta Radiol.* 1995; 36(Suppl.399):2-18.  
3. Visipaque [prescribing information]. Marlborough, MA: GE HealthCare; 2022.

## IMPORTANT SAFETY INFORMATION

### WARNINGS AND PRECAUTIONS:

- **Contrast Induced Acute Kidney Injury:** Acute injury including renal failure can occur. Minimize dose and maintain adequate hydration to minimize risk.

### ADVERSE REACTIONS:

- Serious, life-threatening, and fatal reactions, mostly of cardiovascular origin, have been associated with the administration of iodine-containing contrast agents, including Visipaque Injection.
- Most common adverse reactions (incidence greater than 0.5%) in adult patients after Visipaque injection: Discomfort, warmth, pain; Cardiovascular: angina. Gastrointestinal: diarrhea, nausea, vomiting. Nervous System: agitation, anxiety, insomnia, nervousness, dizziness, headache, migraine, unusual skin sensations, sensory disturbance, fainting, sensation of spinning. Skin: itchy rash, severe itching, hives. Special Senses: Smell, taste, and vision alteration. Pediatric patients experienced similar adverse reactions.

Please see additional Important Safety Information about Visipaque, including Boxed Warning, on page 2 and Full Prescribing Information given to you before this meeting.



# Evolution of contrast media

## Key message

Reduction in osmolality has been a key focus of several trends toward more tolerable contrast media<sup>1,2</sup>

1. Jakobsen JA. *Eur J Radiol.* 2007;62(Suppl.):s14-25.
2. Pedersen HK. *Acta Radiol. Suppl* 1996;37(Suppl.405):1-31.



# Impact of osmolality

Fluid shifts


Myocardial  
effects

Microcirculatory  
changes

# How electrolyte composition might have important electrophysiological and hemodynamic effects



*In vivo studies suggest concentrations of key electrolytes in CM are generally lower than those present in blood<sup>1,2</sup>*



Adapted from Pedersen HK. 1996. + Jynge P. 1996.

Many CM effects on the myocardium may be due to the imbalance between intracellular and extracellular electrolytes<sup>1</sup>

Low intracellular  $\text{Ca}^{2+}$  levels can diminish the force of ventricular contraction during systole, while low intracellular  $\text{Na}^+$  levels can interfere with normal depolarization<sup>3</sup>

## IMPORTANT SAFETY INFORMATION

### ADVERSE REACTIONS:

- Serious, life-threatening, and fatal reactions, mostly of cardiovascular origin, have been associated with the administration of iodine-containing contrast agents, including Visipaque Injection.
- Most common adverse reactions (incidence greater than 0.5%) in adult patients after Visipaque injection: Discomfort, warmth, pain; Cardiovascular: angina. Gastrointestinal: diarrhea, nausea, vomiting. Nervous System: agitation, anxiety, insomnia, nervousness, dizziness, headache, migraine, unusual skin sensations, sensory disturbance, fainting, sensation of spinning. Skin: itchy rash, severe itching, hives. Special Senses: Smell, taste, and vision alteration. Pediatric patients experienced similar adverse reactions.


Please see additional Important Safety Information about Visipaque, including Boxed Warning, on page 2 and Full Prescribing Information given to you before this meeting.

CM, contrast medium/media

1. Pedersen HK. *Acta Radiol Suppl.* 1996;37(Suppl.405):1-31.
2. Jynge P. *Eur Radiol.* 1996; 6(Suppl.2):S8-S12.
3. Chai C-M et al. *Acad Radiol.* 2004;11(5):583-593.

# How osmolality might influence cardiac function

The osmolality of a CM is an important predictor of its cardiac effects;  
the greater the osmolality, the more likely and pronounced the change *in vitro*<sup>1</sup>



CM, contrast medium/media

1. Spencer CM, Goa KL. *Drugs*. 1996; 52(6): 899–927.
2. Swanson DP et al. In: *Pharmaceuticals in Medical Imaging*. Collier MacMillan Publishers, London 1990.

## IMPORTANT SAFETY INFORMATION

### ADVERSE REACTIONS:

- **Cardiovascular Reactions:** Life-threatening or fatal cardiovascular reactions, including hypotension, shock, and cardiac arrest have occurred with the use of Visipaque. Most deaths occur during injection or five to ten minutes later, with cardiovascular disease as the main aggravating factor. Use the lowest necessary dose of Visipaque in patients with congestive heart failure.
- **Thromboembolic Events:** Serious, rarely fatal, thromboembolic events causing myocardial infarction and stroke can occur during angiocardiology procedures with both ionic and nonionic contrast agents.

Please see additional Important Safety Information about Visipaque, including Boxed Warning, on page 2 and Full Prescribing Information given to you before this meeting.

# Visipaque may help to minimize impact on red blood cells<sup>1,2</sup>

Fluid shift from red blood cells can drastically change cell morphology<sup>3</sup>


- this may affect capillary perfusion with a substantial rise in flow resistance<sup>4,5</sup>
- microcirculation disturbances may adversely affect tissue oxygen supply<sup>4,5</sup>



Percentage of normal erythrocytes following 5-minute incubation in vitro in 40% solutions<sup>1</sup>


56%

Saline




73%

Visipaque 320




21%

Iohexol 350



12%

Iopromide 370



Adapted from Jung F et al. 2008.  
Images courtesy of Professor Jung, Centre for Biomaterial Development, GKSS Research Centre, Teltow, Germany

1. Jung F et al. *Clin Hemorheol Microcirc.* 2008;38(1):1-11.
2. Kerl JM et al. *Acta Radiol.* 2008; 49(3):337-343.
3. Gerk U et al. *Clin Hemorheol Microcirc.* 2014;58(1):171-174.
4. Mrowietz C et al. *Clin Hemorheol Microcirc.* 2012;50(1-2):35-47.
5. Jung F et al. *Clin Hemorheol Microcirc.* 2003;29(1):53-61.

## IMPORTANT SAFETY INFORMATION


### WARNINGS AND PRECAUTIONS:

- **Hypertensive Crisis in Patients With Pheochromocytoma:** Hypertensive crisis has occurred after the use of iodinated contrast agents in patients with pheochromocytoma. Inject the minimum amount of contrast necessary, assess the blood pressure throughout the procedure, and have measures for treatment of a hypertensive crisis readily available.
- **Sickle Cell Crisis in Patients With Sickle Cell Disease:** Iodinated contrast agents when administered intravascularly may promote sickling in individuals who are homozygous for sickle cell disease.

Please see additional Important Safety Information about Visipaque, including Boxed Warning, on page 2 and Full Prescribing Information given to you before this meeting.

# In vitro data suggest that Visipaque may help to minimize impact on endothelial cells<sup>1-3</sup>

The impact of CM on capillary endothelial cells may also affect the microcirculation:<sup>1,2</sup>



*Buckling of endothelial cells*  
*Reducing luminal area of the capillary*  
*Potential to impede capillary blood flow*  
 In addition, damage to endothelial cells may result in deterioration of their function<sup>2</sup>

| Endothelial damage                | In vitro results   |
|-----------------------------------|--|
| Distortion of cells               | Change in endothelial cell height compared to control after 1.5 minutes incubation: <sup>1</sup><br>iopromide: +95%, <i>P</i> =0.0065      iodixanol: +12%, <i>P</i> =NS |
| Cell detachment                   | Number of dissolved cell contacts per 220 cells 5 minutes after exposure: <sup>2</sup><br>iomeprol: 41.7      iodixanol: 18.4 <i>P</i> =0.0018                           |
| Exposure of subendothelial matrix | Number of denuded subendothelial areas per 220 cells 5 minutes after exposure: <sup>2</sup><br>iomeprol: 3.07      iodixanol: 2.36 <i>P</i> =0.0353                      |



CM, contrast medium/media  
 NS, not significant

1. Franke RP et al. *Microvasc Res.* 2008;76(2):110-113.
2. Franke RP et al. *Clin Hemorheol Microcirc.* 2011;48(1):41-56.
3. Barstad RM et al. *Acta Radiol.* 1996;37(6):954-961.

## IMPORTANT SAFETY INFORMATION

### WARNINGS AND PRECAUTIONS:

- **Contrast Induced Acute Kidney Injury:** Acute injury including renal failure can occur. Minimize dose and maintain adequate hydration to minimize risk.
- **Severe Cutaneous Adverse Reactions:** Severe cutaneous adverse reactions (SCARs) may develop from one hour to several weeks after intravascular contrast agent administration. These reactions include Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN), acute generalized exanthematous pustulosis (AGEP), and drug reaction with eosinophilia and systemic symptoms (DRESS). Avoid administering Visipaque to patients with a history of a SCAR to Visipaque.
- **Hypertensive Crisis in Patients With Pheochromocytoma:** Hypertensive crisis has occurred after the use of iodinated contrast agents in patients with pheochromocytoma. Inject the minimum amount of contrast necessary, assess the blood pressure throughout the procedure, and have measures for treatment of a hypertensive crisis readily available.

Please see additional Important Safety Information about Visipaque, including Boxed Warning, on page 2 and Full Prescribing Information given to you before this meeting.



# Impact of osmolality

## Key message

Both *in vivo* and *in vitro* data suggest an important connection between CM osmolality and cardiac function

CM, contrast medium/media



# Utility of Visipaque

Indicated in  
adult and  
pediatric  
populations

For both IA  
procedures

And IV  
procedures

IA, intra-arterial  
IV, intravenous



## Indications

# Intra-arterial (IA) administration<sup>1</sup>

### Visipaque is indicated for:

- Intra-arterial digital subtraction angiography for adult and pediatric patients 12 years of age and older with the 270 and 320 mg of iodine/mL doses
- Angiocardiology (left ventriculography and selective coronary arteriography), peripheral arteriography, visceral arteriography, and cerebral arteriography for adult and pediatric patients 12 years of age and older with the 320 mg iodine/mL dose
- Angiocardiology, cerebral arteriography, and visceral arteriography for pediatric patients less than 12 years of age with the 320 mg iodine/mL dose



### Adult indications

(12 years and older)



### Pediatric indications

## IMPORTANT SAFETY INFORMATION

### WARNING: NOT FOR INTRATHECAL USE

Inadvertent intrathecal administration may cause death, convulsions/seizures, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, rhabdomyolysis, hyperthermia, and brain edema.

### CONTRAINDICATION:

Visipaque injection is contraindicated for intrathecal use.

Please see additional Important Safety Information about Visipaque, including Boxed Warning, on page 2 and Full Prescribing Information given to you before this meeting.

1. Visipaque [prescribing information]. Marlborough, MA: GE HealthCare; 2022.



## Indications

# Intra-arterial (IA) administration<sup>1</sup>

### Adult indications

(12 years and older)

|                          | ARTERIOGRAPHY |             | IA-DSA      |             | Maximum dose                 |
|--------------------------|---------------|-------------|-------------|-------------|------------------------------|
|                          | 270 mg I/mL   | 320 mg I/mL | 270 mg I/mL | 320 mg I/mL |                              |
| Carotid arteries         | n/a           | 10-14 mL    | n/a         | 5-8 mL      | Usually not to exceed 175 mL |
| Vertebral arteries       | n/a           | 10-12 mL    | n/a         | 5-8 mL      |                              |
| Right coronary artery    | n/a           | 3-8 mL      | n/a         | n/a         | Usually not to exceed 200 mL |
| Left coronary artery     | n/a           | 3-10 mL     | n/a         | n/a         |                              |
| Left ventricle           | n/a           | 20-45 mL    | n/a         | n/a         |                              |
| Renal arteries           | n/a           | 8-18 mL     | 10-25 mL    | n/a         | Usually not to exceed 250 mL |
| Aortography              | n/a           | 30-70 mL    | 20-50 mL    | 10-50 mL    |                              |
| Major branches of aorta  | n/a           | 10-70 mL    | 5-30 mL     | 2-10 mL     |                              |
| Peripheral arteriography | n/a           | 15-30 mL    | n/a         | 3-15 mL     |                              |
| Aortofemoral runoff      | n/a           | 20-90 mL    | n/a         | 6-15 mL     |                              |

IA, intra-arterial  
DSA, digital subtraction  
angiography

1. Visipaque [prescribing information]. Marlborough, MA: GE HealthCare; 2022.

### IMPORTANT SAFETY INFORMATION

#### WARNINGS AND PRECAUTIONS:



- **Geriatric Use:** While no overall differences in safety or effectiveness were observed in patients >65 years, greater sensitivity regarding some older individuals cannot be ruled out.
- **Contrast Induced Acute Kidney Injury:** Acute injury including renal failure can occur. Minimize dose and maintain adequate hydration to minimize risk.

Please see additional Important Safety Information about Visipaque, including Boxed Warning, on page 2 and Full Prescribing Information given to you before this meeting.



Indications

# Intra-arterial (IA) administration<sup>1</sup>

|  <b>Pediatric indications</b> | ARTERIOGRAPHY |             | IA-DSA      |             |  <b>Maximum dose</b> |
|--|---------------|-------------|-------------|-------------|---|
|  | 270 mg I/mL   | 320 mg I/mL | 270 mg I/mL | 320 mg I/mL |   |
| Cerebral arteriography   | n/a           | 1-2 mL/kg   | n/a         | n/a         | Not to exceed 4 mL/kg   |
| Angiocardiography  | n/a           | 1-2 mL/kg   | n/a         | n/a         |   |
| Visceral arteriography   | n/a           | 1-2 mL/kg   | n/a         | n/a         |   |

IA, intra-arterial  
DSA, digital subtraction angiography

1. Visipaque [prescribing information]. Marlborough, MA: GE HealthCare; 2022.

**IMPORTANT SAFETY INFORMATION**

**WARNINGS AND PRECAUTIONS:**

- Pediatric Use:** Pediatric patients at high risk of adverse reactions during and after administration of contrast agents include those with asthma, hypersensitivity to other medication and/or allergens, cyanotic and acyanotic heart disease, chronic heart failure, or a serum creatinine >1.5 mg/dL. Patients with immature renal function or dehydration may be at increased risk due to prolonged elimination of iodinated contrast agents.

Please see additional Important Safety Information about Visipaque, including Boxed Warning, on page 2 and Full Prescribing Information given to you before this meeting.



## Indications

# Intravenous (IV) administration<sup>1</sup>

### Visipaque is indicated for:

- CT imaging head and body, and excretory urography for adult and pediatric patients 12 years of age and older, with the 270 and 320 mg of iodine/mL doses
- Peripheral venography for adult and pediatric patients 12 years of age and older with the 270 mg of iodine/mL dose
- Coronary computed tomography angiography to assist diagnostic evaluation of patients with suspected coronary artery disease for adult and pediatric patients 12 years of age and older with the 320 mg iodine/mL dose
- CT imaging of the head and body and excretory urography for pediatric patients less than 12 years of age with the 270 mg iodine/mL dose



### Adult indications

(12 years and older)



### Pediatric indications

CT, computed tomography

1. Visipaque [prescribing information]. Marlborough, MA: GE HealthCare; 2022.

## IMPORTANT SAFETY INFORMATION

### WARNING: NOT FOR INTRATHECAL USE

Inadvertent intrathecal administration may cause death, convulsions/seizures, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, rhabdomyolysis, hyperthermia, and brain edema.

### CONTRAINDICATION:

Visipaque injection is contraindicated for intrathecal use.

Please see additional Important Safety Information about Visipaque, including Boxed Warning, on page 2 and Full Prescribing Information given to you before this meeting.

**VISIPAQUE™**  
(IODIXANOL) INJECTION



## Indications

# Intravenous (IV) administration<sup>1</sup>

### Adult indications



|   | 270<br>mg I/mL          | 320<br>mg I/mL                   | Maximum<br>dose |
|---|-------------------------|----------------------------------|-----------------|
| Computed tomography imaging, head or body | 75-150 mL<br>100-150 mL | 75-150 mL<br>100-150 mL          | 150 mL          |
| Excretory urography                       | 1 mL/kg                 | 1 mL/kg                          | 100 mL          |
| Peripheral venography                     | 50-150 mL               | n/a                              | 250 mL          |
| Coronary computed tomography angiography  | n/a                     | 50-150 mL<br>(4-7 mL per second) | 150 mL          |

For pediatric patients 12-17 years, the recommended dose is 1-2 mL/kg

1. Visipaque [prescribing information]. Marlborough, MA: GE HealthCare; 2022.

### IMPORTANT SAFETY INFORMATION

#### WARNINGS AND PRECAUTIONS:

- **Geriatric Use:** While no overall differences in safety or effectiveness were observed in patients >65 years, greater sensitivity regarding some older individuals cannot be ruled out.
- **Contrast Induced Acute Kidney Injury:** Acute injury including renal failure can occur. Minimize dose and maintain adequate hydration to minimize risk.

Please see additional Important Safety Information about Visipaque, including Boxed Warning, on page 2 and Full Prescribing Information given to you before this meeting.



## Indications

# Intravenous (IV) administration<sup>1</sup>

### Pediatric indications



|                                   | 270<br>mg I/mL | 320<br>mg I/mL | Maximum<br>dose       |
|-----------------------------------|----------------|----------------|-----------------------|
| Computed tomography imaging, head | 1-2 mL/kg      | n/a            | Not to exceed 2 mL/kg |
| Computed tomography imaging, body | 1-2 mL/kg      | n/a            |                       |
| Excretory urography               | 1-2 mL/kg      | n/a            |                       |

1. Visipaque [prescribing information]. Marlborough, MA: GE HealthCare; 2022.

### IMPORTANT SAFETY INFORMATION

#### WARNINGS AND PRECAUTIONS:

- Pediatric Use:** Pediatric patients at high risk of adverse reactions during and after administration of contrast agents include those with asthma, hypersensitivity to other medication and/or allergens, cyanotic and acyanotic heart disease, chronic heart failure, or a serum creatinine >1.5 mg/dL. Patients with immature renal function or dehydration may be at increased risk due to prolonged elimination of iodinated contrast agents.

Please see additional Important Safety Information about Visipaque, including Boxed Warning, on page 2 and Full Prescribing Information given to you before this meeting.

# Iodine conversion guide<sup>1</sup>



## Grams of iodine conversion

| Concentration (mg/mL) | 50 mL    | 60 mL    | 70 mL    | 80 mL    | 90 mL    | 100 mL   | 110 mL   | 120 mL   | 130 mL   | 140 mL   |
|-----------------------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|
| <b>270</b>            | 13.5 g/L | 16.2 g/L | 18.9 g/L | 21.6 g/L | 24.3 g/L | 27.0 g/L | 29.7 g/L | 32.4 g/L | 35.1 g/L | 37.8 g/L |
| <b>320</b>            | 16.0 g/L | 19.2 g/L | 22.4 g/L | 25.6 g/L | 28.8 g/L | 32.0 g/L | 35.2 g/L | 38.4 g/L | 41.6 g/L | 44.8 g/L |

| Concentration (mg/mL) | 150 mL   | 160 mL   | 170 mL   | 180 mL   | 190 mL   | 200 mL   | 210 mL   | 220 mL   | 230 mL   | 240 mL   | 250 mL   |
|-----------------------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|
| <b>270</b>            | 40.5 g/L | 43.2 g/L | 45.9 g/L | 48.6 g/L | 51.3 g/L | 54.0 g/L | 56.7 g/L | 59.4 g/L | 62.1 g/L | 64.8 g/L | 67.5 g/L |
| <b>320</b>            | 48.0 g/L | 51.2 g/L | 54.4 g/L | 57.6 g/L | 60.8 g/L | 64.0 g/L | 67.2 g/L | 70.4 g/L | 73.6 g/L | 76.8 g/L | 80.0 g/L |

For adults, the maximum recommended total dose of iodine is 80 grams. For the pediatric population, the maximum recommended total dose of iodine has not been established.

In patients less than 12 years of age, the maximum dose should not exceed 4 mL/kg for intra-arterial administrations and 2 mL/kg for intravenous administrations.

Please see Important Safety Information about Visipaque, including Boxed Warning, on page 2 and Full Prescribing Information given to you before this meeting.

1. Visipaque [prescribing information]. Marlborough, MA: GE HealthCare; 2022.

# Prepared for your patients

Visipaque was designed

to minimize effects on red blood cells<sup>1-3</sup>

to be less irritating to vessel walls<sup>1,4-6</sup>

to have small effects on contractile force<sup>1,7,8</sup>

to minimize dysrhythmic potential<sup>1,9</sup>

## IMPORTANT SAFETY INFORMATION

### WARNINGS AND PRECAUTIONS:

- **Contrast Induced Acute Kidney Injury:** Acute injury including renal failure can occur. Minimize dose and maintain adequate hydration to minimize risk.
- **Cardiovascular Reactions:** Life-threatening or fatal cardiovascular reactions, including hypotension, shock, and cardiac arrest have occurred with the use of Visipaque. Most deaths occur during injection or five to ten minutes later, with cardiovascular disease as the main aggravating factor. Use the lowest necessary dose of Visipaque in patients with congestive heart failure.
- **Thromboembolic Events:** Serious, rarely fatal, thromboembolic events causing myocardial infarction and stroke can occur during angiocardiology procedures with both ionic and nonionic contrast agents.
- **Sickle Cell Crisis in Patients With Sickle Cell Disease:** Iodinated contrast agents when administered intravascularly may promote sickling in individuals who are homozygous for sickle cell disease.

Please see additional Important Safety Information about Visipaque, including Boxed Warning, on page 2 and Full Prescribing Information given to you before this meeting.



1. Almén T. *Acta Radiol.* 1995;36(Suppl.399):2-18.
2. Jung F et al. *Clin Hemorheol Microcirc.* 2008;38(1):1-11.
3. Kerl JM et al. *Acta Radiol.* 2008;49(3):337-343.
4. Franke RP et al. *Microvasc Res.* 2008;76(2):110-113.
5. Franke RP et al. *Clin Hemorheol Microcirc.* 2011;48(1):41-56.
6. Barstad RM et al. *Acta Radiol.* 1996;37(6):954-961.
7. Christiansen C. *Toxicology.* 2005;209(2):185-187.
8. Spencer CM, Goa KL. *Drugs.* 1996;52(6):899-927.
9. Chai CM et al. *Acta Radiol.* 2008;49(2):150-156.



**Customer Service 800 292 8514**

**Medical Affairs 800 654 0118 or  
medical.affairs@gehealthcare.com**

**Reimbursement Hotline 800 767 6664**

**www.gehealthcare.com**

© 2024 GE HealthCare  
Visipaque is a trademark of GE HealthCare.  
GE is a trademark of General Electric Company used under trademark license.  
April 2024 JB00192US

**VISIPAQUE™**  
(IODIXANOL) INJECTION